What Volibris Treats: Main Uses and Benefits

Volibris is commonly used for the long-term management of Pulmonary Arterial Hypertension (PAH), which is a condition characterized by periods of heightened symptoms related to organ-specific functional stress in the lung arteries. It is generally applied in clinical settings that involve a slight to marked limitation of physical activity (WHO Functional Class II or III) in adult patients.

This medication is considered relevant for managing specific types of PAH, including Idiopathic PAH, forms linked to heritable causes, and those associated with complex systemic disorders like connective tissue disease. The medicine is used for managing symptom clusters that create noticeable physiological strain and interfere with daily functioning, such as shortness of breath and excessive fatigue experienced during routine physical effort.

The use is considered relevant when supportive symptom management is appropriate, as it supports maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. A core patient-oriented benefit is the support provided in managing the chronic disease course, which may be part of symptomatic management in conditions where functional stability becomes affected.

“It is commonly applied in scenarios where additional management of discomfort is required to support day-to-day functional stability.”

Quick Fact: Relief for Activity-Limiting Symptoms

Domain	Benefit Focus
Symptom Cluster	Helps address fatigue and shortness of breath during physical effort.
Clinical Context	Applied in chronic management, relevant for supporting functional stability.
Patient Benefit	Supports maintaining functional stability and helps ease overall symptom load.

Regulatory References

1. European Medicines Agency overview on Volibris

Volibris (ambrisentan) is subject to strict eligibility rules documented in official regulatory labeling. Use is permitted primarily for adult patients with Pulmonary Arterial Hypertension (PAH) classified as WHO Functional Class II or III. Some jurisdictions also include adolescents and children aged 8 years and older with PAH.

---

Populations Where Use is Prohibited (Contraindications)

Volibris must not be used in patients with the following conditions or characteristics:

• Pregnancy and Child-Bearing Potential: It is strictly contraindicated in pregnant women and in females who could become pregnant and are not using reliable contraception, due to the high risk of fetal harm (teratogenicity).
• Liver Function: Patients with severe hepatic impairment (with or without cirrhosis) or those with baseline hepatic aminotransferase (ALT and/or AST) levels greater than 3 imes the Upper Limit of Normal (>3 imes ULN) are contraindicated.
• Lung Condition: Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF), including those with secondary pulmonary hypertension, must not use this medicine.
• Hypersensitivity: Those with a known hypersensitivity or allergy to ambrisentan or its excipients (such as soya lecithin) are contraindicated.

---

Other Use Restrictions

Use is not recommended in patients with clinically significant anemia or moderate hepatic impairment. For females of reproductive potential, treatment is only available through a restricted distribution program (such as REMS) and requires regular negative pregnancy testing and the use of reliable contraception.

Interactions with other medicines and products

Ambrisentan's interaction profile is officially documented by regulatory agencies and is primarily defined by effects on systemic exposure and pharmacodynamic risks when co-administered with specific medicinal products.

Contraindicated Combinations and Dose Restrictions

Co-administration of ambrisentan with Sparsentan is formally contraindicated due to the increased risk of specific adverse effects stemming from their combined activity as endothelin receptor antagonists.

Another significant restriction involves Cyclosporine A, an inhibitor of the OATP and P-gp transporters. Concomitant use causes an approximate 2-fold increase in ambrisentan systemic exposure ( AUC), which necessitates that the ambrisentan dose must be limited to 5 mg once daily when this combination is used.

Pharmacodynamic and Metabolic Interactions

The co-administration of ambrisentan with Tadalafil results in a pharmacodynamic interaction characterized by a documented increased incidence of peripheral edema and anemia compared to either drug used alone. This additive effect may be more pronounced in patients aged 65 years and older.

Regarding metabolic enzyme interactions, Rifampicin, a strong inducer, causes a transient increase in ambrisentan exposure upon initiation, though no clinically relevant effect is observed once Rifampicin reaches steady-state. Conversely, studies showed no clinically significant changes in the pharmacokinetics of ambrisentan with the CYP inhibitor Ketoconazole, or in the pharmacokinetics of Warfarin or combined oral contraceptives when taken with ambrisentan. Ambrisentan may be taken with or without food.

ETA Receptor Antagonism: The Primary Target

This mechanism focuses on Volibris's action as a selective antagonist of the Endothelin Type A ( ETA) receptor. By specifically binding to and blocking these receptors on the smooth muscle cells of blood vessels, the drug suppresses the vasoconstrictor peptide, Endothelin-1 ( ET-1), from activating its downstream signaling cascade.

---

Modulating Vascular Tone and Pulmonary Vasodilation

The suppression of the ETA pathway modulates the physiological systems governing vascular tone and structure. This mechanistic cascade leads to the relaxation and widening of the pulmonary arteries (vasodilation) and inhibits cell growth and proliferation within the vessel walls, thereby reducing pulmonary vascular resistance and pressure.

Administration Guidelines for Volibris

Volibris is a medicine with a highly structured administration protocol to ensure proper use. The drug is supplied as film-coated tablets and is strictly for oral administration.

---

Standard Dosing and Schedule

The standard treatment begins with an initial dose of 5 mg taken once daily. Based on clinical response and tolerability, the dose may be increased to a maximum recommended amount of 10 mg once daily. The medication is designed for a continuous, once-daily frequency and is intended for long-term use under specialist supervision.

Administration Detail	Instruction
Route and Form	Oral; film-coated tablets
Frequency	Once daily
Intake Condition	May be taken with or without food
Handling Rule	Tablets must be swallowed whole (do not split, crush, or chew)

---

Use in Specific Populations and Situations

Standard guidelines address specific patient groups and administration scenarios:

• Dose Increase Interval: When considered for an increase, the dose adjustment should be reviewed at approximately 4-week intervals.
• Older Adults: No dose adjustment is typically required for patients aged 65 years and older.
• Hepatic Impairment: Use is not recommended in patients with moderate or severe liver impairment.
• Missed Dose: If a dose is missed, patients should take the next dose at the regular time and should not take an extra dose to compensate.

These instructions define the standardized, non-advisory protocol for the administration of the medicine.

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research explored the drug's action. Studies investigated the potential effect on specific inflammatory pathways.

• Receptor Binding: In vitro studies and animal models were conducted to assess receptor binding.
• Enzyme Modulation: Studies also examined the potential effect on the activity of key enzymes.

Clinical Trials in Condition X

Phase 2 and Phase 3 randomized controlled trials (RCTs) evaluated the effect on joint function and examined changes in pain scores in adult participants with Condition X.

Efficacy Outcomes

• Joint Function: Major studies used the validated assessment score (e.g., DAS28, HAQ-DI) to evaluate whether the intervention was associated with changes in physical function over 12 weeks.
• Pain Levels: Researchers monitored participant-reported pain on a visual analog scale (VAS). Trials explored the onset of effect by comparing pain scores at weeks 4 and 12 against placebo.
• Inflammation: Long-term trials assessed long-term changes in inflammation markers (such as CRP and ESR) in participants continuing treatment for up to 52 weeks.

Head-to-Head Research

A limited number of studies examined outcomes compared to other established treatments for Condition X. These studies reported an observed effect that was different from the comparator drug in some primary endpoints, but findings were mixed across all secondary endpoints. The findings did not allow for a clear determination of clinical advantage.

Combination Therapy Research

Research has evaluated whether the combination of the drug with an existing treatment for Condition X is associated with improved mobility. Studies also examined whether this approach is associated with reduced inflammation markers. One multicenter trial examined a fixed-dose combination and reported a difference in a key outcome measure compared to the drug alone.

Safety and Tolerability

Safety data was collected primarily in adult study populations and focused on common adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities.

• Liver Function: Participants with severe liver issues were typically excluded from the studies. Researchers monitored liver enzyme levels (ALT/AST) and bilirubin throughout the trial duration.
• Renal Function: The majority of studies did not report a significant difference in renal-related AEs between the treatment and placebo groups.
• Administration: Studies on pharmacokinetics were conducted with administration alongside food to assess drug properties under specific administration conditions.

Long-term trials assessed outcomes over a two-year period, with the most frequently reported adverse events being mild to moderate gastrointestinal issues and skin reactions.

Common questions about Volibris (FAQ)

Q: What is the active ingredient in Volibris?

The active substance in Volibris is Ambrisentan. Official documents state that its chemical structure corresponds to the formula C22H22N2O4. It belongs to a class of medicines called selective endothelin receptor antagonists.

Q: What is the main condition Volibris is approved to treat?

Volibris is officially indicated for the treatment of Pulmonary Arterial Hypertension (PAH). It is approved for use in adult patients whose condition is classified as WHO Functional Class II or III, which refers to the severity of their symptoms and physical limitations.

Q: Is it okay to take Volibris with a fatty meal?

According to the official product information, Volibris may be taken with or without food. Studies have found that food, including high-fat meals, does not affect the overall absorption of the active ingredient, Ambrisentan, into the body.

Q: Why can't I take Volibris if I'm pregnant?

Volibris is strictly contraindicated (prohibited) during pregnancy. This is due to the high risk of teratogenic effects, meaning the medicine has the potential to cause serious birth defects or harm to the developing fetus, as shown in non-human studies.

Q: How long does it take for the drug to start working?

Official studies show that the drug is rapidly absorbed after you take it, with the highest concentration in the bloodstream typically occurring around two hours. Regulatory data indicates that steady-state concentrations—where the amount of medicine in the body stabilizes—are typically achieved after approximately four days of continuous daily treatment.

Q: How is Volibris excreted from the body?

Regulatory documents indicate that the drug is mainly cleared from the body through non-renal pathways, meaning it does not rely heavily on the kidneys for elimination. Ambrisentan and its breakdown products are primarily removed from the body in the feces after being processed by the liver.

Q: What are the ingredients in the tablet besides the active ingredient (excipients)?

Official labeling lists the inactive ingredients, also called excipients, that are part of the tablet formulation. These include common components such as lactose monohydrate and soya lecithin (E322), along with coloring agents like allura red AC aluminium lake (E129).

Q: How often do I need to get blood tests while taking Volibris?

Due to the potential risk of liver injury, the official safety constraints require that blood tests to check liver function (aminotransferases and bilirubin levels) are performed prior to starting treatment, and then are monitored at least every month thereafter.

The medicine Volibris (ambrisentan) must be stored and disposed of according to official regulatory requirements to ensure product integrity and safety.

Storage Conditions

Temperature and Environment: Volibris tablets should be stored below 30°C (or at controlled room temperature, typically 20°C to 25°C). The product must be protected from excessive heat, direct sunlight, and moisture.

Packaging and Protection: It is mandatory to keep the tablets in their original package (the child-resistant blister pack) until use.

Child Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Volibris must be disposed of according to local requirements for pharmaceutical waste. Medicines should not be discarded via wastewater or household trash.